Company intelligence / Profile preview
Zein Healthcare
- Ownership
- Private
- Development stage
- Other
Overview
Zein Biotechnology is a leading Chinese pharmaceutical company with over 50 ongoing projects across pharmaceuticals, biopharmaceuticals, and traditional Chinese medicine. The company has developed proprietary synthesis routes for drugs like orlistat and holds numerous patents. It has received multiple new drug certificates and production licenses from regulatory authorities such as the SFDA. Its main products include orlistat capsules ("YASU") and tropisetron hydrochloride for injection ("SAIGEEN"), both first launched in China. The company operates under cGMP standards with a global sales network.
- Therapeutic areas
- OncologyMetabolic DisordersEndocrinologyImmunologyGastroenterologyCardiovascularNeurology
- Modalities
- Small moleculeBiologicTraditional Chinese medicineVaccine
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Zein Healthcare.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zein Healthcare.